熱門資訊> 正文

TMF Pharmaceuticals在第三季度表现强劲后上调25财年指引

2025-10-14 15:51

Telix Pharmaceuticals (OTCPK:TLPPF) reported Q3 2025 revenue of $206M, up 53% year-over-year.
FY 2025 revenue guidance raised to $800–$820 million, up from prior forecasts.
R&D spending to rise 20–25% in FY 2025 to support growing clinical pipeline.
PSMA imaging revenue hit $155M, while RLS third-party revenue contributed $47M in Q3.

More on Telix Pharmaceuticals

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable
Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment
Historical earnings data for Telix Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。